[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"degenerative-disc-disease-ddd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:degenerative-disc-disease-ddd":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100640600","pmcf-study-on-the-effectiveness-and-safety-of-metrosan-spinal-systems-and-bonegraft-filling-materials-100640600",false,"NCT07615491","PMCF Study on the Effectiveness and Safety of METROSAN Spinal Systems and BONEGRAFT Filling Materials","A Prospective, Multi-Center, Observational Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Effectiveness and Safety of METROSAN Spinal Systems and BONEGRAFT Filling Materials Used in Spinal Instrumentation and Fusion Surgery","INFO SPINE","Inclusion Criteria:\n\n* 18 years of age or older.\n* Skeletally mature.\n* Male or female.\n* Undergone spinal surgery (cervical or thoracolumbar) for any indication under current medical practice.\n* Titania® spinal stabilization\u002Ffusion systems and\u002For BONEGRAFT® bone cements or BONEGRAFT® bone graft materials used during the operation.\n* No general health condition contraindicating surgery.\n* No legal restriction (military service, incarceration, or equivalent).\n* Provision of signed and dated Informed Consent Form (ICF)\n\nExclusion Criteria:\n\n* Participation in another interventional clinical investigation\n* Suspected or confirmed pregnancy\n* Morbid obesity\n* Neurological or psychiatric conditions preventing compliance with postoperative care and instructions\n* Active spinal or systemic infection\n* High fever or leukocytosis\n* Severe osteoporosis and\u002For disease affecting bone metabolism\n* Known allergy or hypersensitivity to PEEK, Titanium, or PMMA\n* Congenital abnormality, tumor, or other condition preventing secure implant fixation or likely to shorten implant useful life\n* Inadequate tissue coverage at the operative site\n* Legally restricted individuals (military personnel, prisoners, etc.)","ALL","18 Years",{"count":20,"type":21},561,"ESTIMATED","OBSERVATIONAL","This is a prospective, multi-center, observational Post-Market Clinical Follow-Up (PMCF) study designed to collect additional safety and clinical performance data on CE-marked Titania® spinal instrumentation and fusion systems, and Bonegraft® bone filling materials (synthetic bone grafts and bone cements). The study aims to evaluate short-term (12-month) safety and effectiveness, identify previously unknown side effects, monitor defined complications, and assess risks based on real-world evidence in patients undergoing spinal surgery. All investigated products are used within their intended purpose under routine clinical practice.",[25,26,27,28,29,30,31,32],"Degenerative Disc Disease (DDD)","Spinal Stenosis","Spondylolisthesis","Spinal Deformities","Spinal Tumors","Spinal Infections","Spinal Trauma","Vertebral Fractures",[34,35,36,37,38,39,40,41,42,43,44,45],"Post-Market Clinical Follow-Up (PMCF)","Spinal Instrumentation","Spinal Fusion","Interbody Fusion","Spinal Stabilization","Spinal Cages","Pedicle Screws","Cervical Plate System","Interspinous Fusion Device","Spinal Implants","Synthetic Bone Graft","Bone Cement","RECRUITING","2026-05-22",{"date":49,"type":50},"2026-05-29","ACTUAL",{"date":52,"type":50},"2026-04-27",{"date":54,"type":21},"2028-09-26",{"name":56,"class":57},"Metrosan End. ve Elk. Mek. Cihazlar ve Tibbi Malz. San. Tic. Ltd. Co.","INDUSTRY",3,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":75,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100516977","hydrafil-d-hydrogel-augmentation-for-intervertebral-lumbar-discs-100516977","NCT06011551","HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs","HYDRAFIL-D","Inclusion Criteria:\n\n* Male or female subjects aged 22 to 85 years, inclusive\n* Subjects presenting with LBP greater than leg pain and symptoms of DDD of the lumbar region (L1- S1) of at least six (6) months duration\n* Presence of one (1) or two (2) symptomatic disc(s) (i.e., only 1-level or 2-levels may be treated during the study) as determined by Discography\n* Symptomatic disc(s) exhibiting Grade 4 to 8 degeneration on the modified Pfirrmann scale as determined by MRI\n* Failure to have their symptoms resolve or reduce following at least six (6) months of conservative care (as defined in the body of the protocol)\n* Psychosocially, mentally and physically able and willing to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms\n* English fluency\n* Signed informed consent\n\nExclusion Criteria:\n\n* History of or active systemic or local infection\n* Any skin disease or inadequate tissue coverage at the site of the proposed injection\n* Annular tear or defect that shows free contrast extravasation into the epidural space during or after Discography\n* Presence of more than two (2) symptomatic discs presenting with pain confirmed during Discography\n* Presence of extruded or sequestered disc herniation (i.e., disc extrusions or sequestrations) at the symptomatic level(s) or on adjacent levels\n* Presence of wide annular fissures confluent with large disc protrusions at the symptomatic level(s)\n* Epidural steroid injection, intradiscal injection, trigger point injection, facet or medial branch block within 60 days of enrollment\n* Opioid medication usage \\>60 MME (morphine milligram equivalent)\u002Fday or increase in opioid use within 60 days of enrollment\n* Evidence of Modic type 3 changes\n* Subjects presenting with radicular pain greater than back pain or by history within the past six (6) months. Radicular pain is defined as nerve pain following a dermatomal distribution and that correlates with nerve compression on imaging. Note: somatic referred pain is allowed\n* Evidence of neurogenic claudication due to spinal stenosis\n* Subjects with any prior back surgery on the lumbar spine\n* History of vertebral fractures in the lumbar spine\n* Evidence of severe compression of cauda equina\n* Evidence of spinal segmental instability (spondylolysis or spondylolisthesis: Grade \\>1), severe spinal canal stenosis, isthmus pathology, or scoliosis \\[Cobb angle \\>20 at the index level(s)\\]\n* Subjects with arachnoiditis\n* Subjects who are prisoners or wards of courts\n* Subjects involved in active litigation including worker's compensation cases\n* Subjects on chronic anticoagulation due to a bleeding disorder and unable to safely stop anticoagulants, or has taken anticoagulants within three (3) days prior to procedure\n* Subjects with LBP of non-spinal or unknown etiology\n* Subjects who have a history (in the last five (5) years) of substance abuse or chemical dependency (pharmaceuticals, illicit drugs, alcohol) or are current abusers (using definition criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-V))\n* Subjects who have major psychiatric disorders, such as major depression, bipolar disorder and schizophrenia, as defined by the DSM-V\n* If female, subjects who are pregnant or are trying to become pregnant during the course of the trial (due to risks of additional radiation exposures)\n* Failure to understand informed consent or inability or unwillingness to adhere to the study follow-up visit schedule or other protocol requirements\n* Subjects having participated in any other clinical study within the last three (3) months, or are actively participating in any other clinical study, or have planned participation in any other clinical study during the course of this trial. Note: subjects must agree they will not participate in any other clinical study during the course of this trial\n* Body Mass Index (BMI) \\>35 kg\u002Fm2\n* Current smoker or nicotine and\u002For tobacco user\n* Known allergy or hypersensitivity to any of the device materials\n* Endocrine or metabolic disorder known to affect osteogenesis\n* Insulin-dependent diabetes mellitus\n* Inability to undergo X-ray, MRI, CT scans or other radiographic assessments, including Discography\n* Any comorbid medical condition which, in the best judgement of the Investigator, would make the subject unsuitable for inclusion in the study or interferes with the proper assessment of safety or effectiveness (e.g., systemic disease)\n* Subjects with any active malignancy or who have been previously diagnosed with a malignancy and have evidence of residual disease\n* Any degenerative or neurological condition that would interfere with evaluation of outcomes or that may generate an unacceptable risk of failure or postoperative complications\n* Chronic or acute renal and\u002F or hepatic impairment\n* Evidence of severe osteoporosis. The SCORES\u002FMORES will be utilized to screen if a DEXA scan is indicated. If SCORES\u002FMORES value ≥ 6; then a DEXA scan is required. Severe osteoporosis is defined as DEXA T-score \\\u003C 2.5 (spine or hip) or QCT T-score \\\u003C 80mg\u002Fcubic cm","22 Years","85 Years",{"count":69,"type":21},225,"INTERVENTIONAL",[72],"NA","A multi-center, prospective, dual arm, randomized, controlled pivotal study to evaluate the safety and effectiveness of the ReGelTec HYDRAFIL™ System.",[25],[76,77,78],"Intervertebral Disc","Nucleus Pulposus","Disc Augmentation","2026-05-07",{"date":81,"type":50},"2026-05-08",{"date":83,"type":50},"2025-01-13",{"date":85,"type":21},"2028-11",{"name":87,"class":57},"ReGelTec, Inc.",14]